WARNING: SERIOUS INFECTIONS, MORTALITY, MALIGNANCY, MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE), AND THROMBOSIS
See full prescribing information for complete boxed warning.
• Serious infections leading to hospitalization or death, including tuberculosis and bacterial, invasive fungal, viral, and other opportunistic infections, have occurred in patients receiving Janus kinase inhibitors for inflammatory conditions. Monitor patients for infection.
• Higher rate of all-cause mortality, including sudden cardiovascular death have been observed in patients treated with Janus kinase inhibitors for inflammatory conditions.
• Lymphoma and other malignancies have been observed in patients treated with Janus kinase inhibitors for inflammatory conditions. Perform periodic skin exams.
• Higher rate of MACE (including cardiovascular death, myocardial infarction, and stroke) has been observed in patients treated with Janus kinase inhibitors for inflammatory conditions.
• Thrombosis, including deep venous thrombosis, pulmonary embolism, and arterial thrombosis, some fatal, have occurred in patients treated with Janus kinase inhibitors for inflammatory conditions.
INDICATIONS
OPZELURA is indicated for the topical treatment of:
• short-term, non-continuous, uncontrolled mild to moderate atopic dermatitis in non-immunocompromised adult and pediatric patients 12 years and older
• nonsegmental vitiligo in adult and pediatric patients 12 years and older
Limitations of Use: Use of OPZELURA in combination with therapeutic biologics, other JAK inhibitors, or potent immunosuppressants such as azathioprine or cyclosporine is not recommended.
Please see full Prescribing Information including Boxed Warning by visiting www.opzelura.com/prescribing-information.pdf.
OPZELURA, the OPZELURA logo, lncyte, and the lncyte logo are registered trademarks of lncyte.
© 2023, lncyte Corporation. MAT-OPZ-02015 11/23
Company Details
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- https://www.opzelurahcp.com
- Keywords
- Nashville.
Opzelura® (Ruxolitinib) Hcp Questions
Opzelura® (Ruxolitinib) Hcp's website is https://www.opzelurahcp.com
Opzelura® (Ruxolitinib) Hcp's LinkedIn profile is https://www.linkedin.com/company/opzelura-hcp
Opzelura® (Ruxolitinib) Hcp's industry is
Pharmaceutical Manufacturing
Opzelura® (Ruxolitinib) Hcp's top competitors are
Pemazyre® (Pemigatinib) Hcp,
Vertex Pharmaceuticals,
Expiritas,
Xywav® (Calcium, Magnesium, Potassium, And Sodium Oxybates),
Jakafi® (Ruxolitinib) Hcp,
Proper Saké Company,
Adbry® (Tralokinumab-Ldrm) Hcp,
Incyte,
Bristol Myers Squibb,
Dupixent® (Dupilumab) Hcp.
Opzelura® (Ruxolitinib) Hcp's categories are Pharmaceutical Manufacturing
